GSK Pharma Q2FY27 profit up 31% to ₹334.6 crore; underlying growth 12-13%
GSK Pharma reported a 31% YoY increase in Q2FY27 net profit to ₹334.6 crore, with revenue up 21% to ₹1,179.9 crore. Underlying growth, excluding base effects, is estimated at 12-13%. The company aims for ₹8,000 crore revenue by FY31, with growth driven by established products and new launches. Management expects double-digit revenue and EBITDA growth, maintaining EBITDA margins around 34%.
How this was made
The 30-second read
Why it matters
The earnings beat and forward outlook provide fresh material for traders; the stock may see a short‑term rally, but margin compression and cash depletion warrant caution.
Market read
First‑time disclosure of Q2FY27 earnings for GSK Pharma; significant for Indian pharma investors and may influence sector sentiment.
What to watch
One‑off tax refund inflates profit; underlying growth may be slower once adjusted.
Background
GlaxoSmithKline Pharmaceuticals Ltd. reported its Q2FY27 results, highlighting a 31% profit increase and 21% revenue growth, with guidance for continued double‑digit expansion.
Ticker impact
Q2FY27 standalone net profit rose 31% YoY to ₹334.6 crore, revenue up 21% and guidance of double‑digit growth.
likely modest upside as market prices in higher profit and revenue growth
Profit beat, revenue expansion and forward guidance are fresh primary data; investors typically react positively to such earnings surprises.
Market effects
Indian pharma sector may see broader rally on strong earnings from a market leader.
Positive earnings could boost NSE pharma index and related stocks.
Limited; mainly affects Indian and emerging‑market investors.
Counterpoint
Margin pressure from raw‑material inflation and cash outflow could temper upside.
Key entities
- companyGlaxoSmithKline Pharmaceuticals Ltd.
Indian pharmaceutical subsidiary of GSK reporting Q2FY27 results.
- executiveRonojit Biswas
CFO who commented on growth outlook.
